Sugi Predict

Sugi Predict / Compounds / SCHEMBL6316335

SCHEMBL6316335

SCHEMBL6316335

CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1cccc2ccccc12)N(C)C(=O)COCC(C)(C)NC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 1/20 0.36
▸ TACR1 P25103 1/20 0.36
▸ METAP2 P50579 1/20 0.35
▸ CTSS P25774 1/20 0.35
▸ CTSK P43235 1/20 0.35
▸ MMP9 P14780 3/20 0.35
▸ MMP2 P08253 2/20 0.34
▸ MMP8 P22894 2/20 0.34
▸ PSMB5 P28074 2/20 0.34
▸ GHSR Q92847 2/20 0.33
▸ KLKB1 P03952 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317442 0.92 CTSS (0.42) HRH4CTSSCTSKMMP9MMP2
SCHEMBL6320214 0.90 HRH4 (0.37) HRH4TACR1METAP2CTSSCTSK
SCHEMBL7063301 0.82 GHSR (0.42) TACR1GHSR
SCHEMBL6317643 0.82 GHSR (0.51) HRH4METAP2MMP9GHSR
SCHEMBL6317654 0.82 GHSR (0.51) HRH4METAP2MMP9GHSR
SCHEMBL8905086 0.82 GHSR (0.51) HRH4METAP2MMP9GHSR
SCHEMBL6317747 0.82 CTSS (0.46) HRH4METAP2CTSSCTSKMMP9
SCHEMBL6318120 0.81 HRH4 (0.45) HRH4METAP2MMP9MMP2MMP8
SCHEMBL6324008 0.78 CTSL (0.39) TACR1CTSSCTSKMMP9MMP2
SCHEMBL6324396 0.76 GHSR (0.46) TACR1CTSSCTSKMMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 — — US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 — — US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 — — US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 — — US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 — — US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 — — US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 — — EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 HRH4 1267/4885TACR1 241/4885METAP2 1489/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR HRH4 976/4885TACR1 232/4885METAP2 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.